{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:18:46Z","timestamp":1782548326285,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009108","name":"Shandong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cmi.2024.09.007","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T09:13:41Z","timestamp":1726650821000},"page":"101-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Drug-drug interactions of simnotrelvir\/ritonavir: an open-label, fixed-sequence, two-period clinical trial"],"prefix":"10.1016","volume":"31","author":[{"given":"Pan-Pan","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bu-Fan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Lin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Guang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Rong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-jia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-sen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aik Han","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun-Wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.09.007_bib2","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1038\/s41467-023-42102-y","article-title":"Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2024.09.007_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106598","article-title":"A\u00a0first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects","volume":"191","author":"Yang","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.cmi.2024.09.007_bib4","article-title":"Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial","volume":"38","author":"Wang","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.cmi.2024.09.007_bib5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral simnotrelvir for adult patients with mild-to-moderate COVID-19","volume":"390","author":"Cao","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2024.09.007_bib6","unstructured":"Food and Drug Administration (FDA). NORVIR. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022417Orig1s025,020659Orig1s073,209512Orig1s008lbl.pdf; 2022. [Accessed 9 September 2023]."},{"key":"10.1016\/j.cmi.2024.09.007_bib7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5414\/CPP48192","article-title":"Effect of saquinavir\/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe","volume":"48","author":"Schmitt","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2024.09.007_bib8","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbagen.2006.09.024","article-title":"The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks","volume":"1770","author":"Plant","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cmi.2024.09.007_bib12","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in\u00a0vitro and in\u00a0vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cmi.2024.09.007_bib13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","article-title":"Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies","volume":"59","author":"Elmeliegy","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2024.09.007_bib15","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1345\/aph.1M393","article-title":"Drug-drug interaction between itraconazole and the protease inhibitor lopinavir\/ritonavir","volume":"43","author":"Hills-Nieminen","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cmi.2024.09.007_bib16","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","article-title":"Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers","volume":"48","author":"la Porte","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2024.09.007_bib17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2024.09.007_bib18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-019-0341-y","article-title":"Guidance for rifampin and midazolam dosing protocols to study intestinal and hepatic cytochrome P450 (CYP) 3A4 induction and de-induction","volume":"21","author":"Kapetas","year":"2019","journal-title":"AAPS J"},{"key":"10.1016\/j.cmi.2024.09.007_bib19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2024.09.007_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management","volume":"3","author":"Ramappa","year":"2013","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.cmi.2024.09.007_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4172\/2161-1068.1000209","article-title":"Current overview of anti-tuberculosis drugs: metabolism and toxicities","volume":"6","author":"Sarkar","year":"2016","journal-title":"Mycobact Dis"},{"key":"10.1016\/j.cmi.2024.09.007_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1753-5174.2009.00017.x","article-title":"Unexpected hepatotoxicity of rifampin and saquinavir\/ritonavir in healthy male volunteers","volume":"2","author":"Schmitt","year":"2009","journal-title":"Arch Drug Inf"},{"key":"10.1016\/j.cmi.2024.09.007_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0b013e318189a7df","article-title":"Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir","volume":"50","author":"Haas","year":"2009","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2024.09.007_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2023.100498","article-title":"Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants","volume":"53","author":"Tamemoto","year":"2023","journal-title":"Drug Metab Pharmacokinet"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24004385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T22:53:04Z","timestamp":1738450384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24004385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1198743X24004385"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.09.007","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-drug interactions of simnotrelvir\/ritonavir: an open-label, fixed-sequence, two-period clinical trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}